Eyegate Pharmaceuticals (EYEG) Receiving Somewhat Positive Press Coverage, Study Finds
News stories about Eyegate Pharmaceuticals (NASDAQ:EYEG) have been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Eyegate Pharmaceuticals earned a news sentiment score of 0.08 on Accern’s scale. Accern also gave news stories about the specialty pharmaceutical company an impact score of 46.8049785786655 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the media headlines that may have effected Accern Sentiment Analysis’s analysis:
- Oxford Immunotec Global PLC (OXFD) registers a price change of 1.61% while Eyegate Pharmaceuticals, Inc. (EYEG … – Stocks Gallery (stocksgallery.com)
- What’s Behind EyeGate Pharmaceuticals Inc (EYEG)’s Movement – Evergreen Caller (evergreencaller.com)
- Uveitis Treatment Market Forecasted to Cross US$ 847.8 Mn by 2024 (medgadget.com)
- EyeGate Pharmaceuticals, Inc. :EYEG-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 (finance.yahoo.com)
- Eyegate Pharmaceuticals Inc. W (EYEGW) Seeing Chaikin MF … – Danville Daily (danvilledaily.com)
Eyegate Pharmaceuticals (NASDAQ:EYEG) traded up 6.00% during mid-day trading on Friday, reaching $1.06. 194,576 shares of the company were exchanged. Eyegate Pharmaceuticals has a 12 month low of $0.90 and a 12 month high of $3.90. The company’s 50 day moving average price is $1.20 and its 200-day moving average price is $1.80. The stock’s market capitalization is $18.24 million.
A number of analysts recently commented on the stock. HC Wainwright set a $6.00 price objective on shares of Eyegate Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, August 8th. Noble Financial reissued a “buy” rating on shares of Eyegate Pharmaceuticals in a report on Friday, May 19th.
Eyegate Pharmaceuticals Company Profile
Eyegate Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.
Receive News & Ratings for Eyegate Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.